Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAFV600 Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 0 results

Not applicableStudy completedNCT04911998
What this trial is testing

A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients

Who this might be right for
Melanoma (Skin)Metastatic MelanomaBRAF V600 Mutation
Pierre Fabre Medicament 400
Early research (Phase 1)Study completedNCT01849666
What this trial is testing

The Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Who this might be right for
Malignant Melanoma, Neoplasms
Hoffmann-La Roche 2
Testing effectiveness (Phase 2)Active Not RecruitingNCT04074096
What this trial is testing

Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis

Who this might be right for
Malignant MelanomaBRAF V600 MutationBrain Metastases
UNICANCER 10
Testing effectiveness (Phase 2)UnknownNCT02625337
What this trial is testing

Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients

Who this might be right for
Metastatic Melanoma
The Netherlands Cancer Institute 32
Testing effectiveness (Phase 2)UnknownNCT02202200
What this trial is testing

Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma

Who this might be right for
Melanoma BRAF V600E/K MutatedCDNKN2A Loss Defined
Assistance Publique - Hôpitaux de Paris 40
Testing effectiveness (Phase 2)Study completedNCT03625141
What this trial is testing

A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases

Who this might be right for
Metastatic Melanoma
Hoffmann-La Roche 80
Early research (Phase 1)Looking for participantsNCT03454035
What this trial is testing

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Who this might be right for
Tumor, SolidPancreatic CancerMelanoma
UNC Lineberger Comprehensive Cancer Center 45
Early research (Phase 1)WithdrawnNCT01765556
What this trial is testing

A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma

Who this might be right for
Malignant Melanoma, Neoplasms
Hoffmann-La Roche
Testing effectiveness (Phase 2)Study completedNCT01320085
What this trial is testing

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Who this might be right for
BRAF or NRAS Mutant Metastatic Melanoma
Pfizer 183
Testing effectiveness (Phase 2)Study completedNCT03915951
What this trial is testing

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Pfizer 98
Early research (Phase 1)Ended earlyNCT02313012
What this trial is testing

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

Who this might be right for
Neoplasm Metastasis
Celgene 19